ACADIA Pharmaceuticals (ACAD) Earnings Date, Estimates & Call Transcripts → The Hard Truth About Investing For Retirement (From Insiders Exposed) (Ad) Free ACAD Stock Alerts $16.30 -0.29 (-1.75%) (As of 03:29 PM ET) Add Compare Share Share EarningsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Earnings SummaryUpcoming Earnings DateMay. 8After Market ClosesConfirmedActual EPS (Feb. 27) $0.28 Missed By -$0.04 Consensus EPS (Feb. 27) $0.32 Read Call TranscriptListen to Call Get ACADIA Pharmaceuticals Earnings AlertsEnter your email address below to receive the latest news and earnings results for ACAD and its competitors with MarketBeat's FREE daily newsletter. Skip Charts & View Estimated and Actual Earnings DataEarnings Per ShareRevenueACAD Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.ACAD Estimated and Actual Revenue by Quarter Estimated Revenue and Actual Revenue by Quarter Chart DescriptionThe chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter. Ad WealthPress$25,000 into $109,616 in two months? Today I want to show you how our research shows you could’ve grown a $25,000 account into $109,616.12 within the last TWO months. You see, former multi-million dollar hedge fund manager Roger Scott spent the better half of 2023 developing what might be the most advanced trading tool that exists… It’s a revolutionary software system that tracks the moves of institutional investors…. in real time…Go here to watch the most recent trading workshop video at no charge. ACADIA Pharmaceuticals Analyst EPS EstimatesQuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateCompany GuidanceQ1 20242($0.01)$0.12$0.06 Q2 20243$0.17$0.26$0.20 Q3 20243$0.17$0.27$0.22 Q4 20243$0.18$0.33$0.24 FY 202411$0.51$0.98$0.72 Q1 20251$0.30$0.30$0.30 Q2 20251$0.22$0.22$0.22 Q3 20251$0.21$0.21$0.21 Q4 20251$0.21$0.21$0.21 FY 20254$0.94$0.94$0.94 Q1 20261$0.41$0.41$0.41 ACAD Earnings Date and InformationACADIA Pharmaceuticals last issued its earnings results on February 27th, 2024. The biopharmaceutical company reported $0.28 EPS for the quarter, missing the consensus estimate of $0.32 by $0.04. The company earned $231.04 million during the quarter, compared to the consensus estimate of $223.79 million. Its revenue for the quarter was up 69.3% on a year-over-year basis. ACADIA Pharmaceuticals has generated ($0.38) earnings per share over the last year (($0.38) diluted earnings per share). Earnings for ACADIA Pharmaceuticals are expected to grow by 88.71% in the coming year, from $0.62 to $1.17 per share. ACADIA Pharmaceuticals has confirmed that its next quarterly earnings report will be published on Wednesday, May 8th, 2024. Read More ACADIA Pharmaceuticals Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years Time Frame * Start Date * End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueCall Transcript 5/8/2024Confirmed)------- 2/27/2024Q4 2023$0.32$0.28($0.04)$0.28$223.79 million$231.04 million 11/2/2023Q3 2023($0.43)($0.40)+$0.03($0.40)$194.40 million$211.70 million8/2/2023Q2 2023($0.12)$0.01+$0.13$0.01$163.86 million$165.20 million 5/8/2023Q1 2023($0.21)($0.27)($0.06)($0.27)$120.29 million$118.46 million 2/27/2023Q4 2022($0.25)($0.26)($0.01)($0.26)$135.18 million$136.49 million 11/2/2022Q3 2022($0.18)($0.17)+$0.01($0.17)$139.04 million$130.70 million Get the Latest News and Ratings for ACAD and Related StocksEnter your email address below to receive the latest news and analysts' ratings for ACADIA Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. 8/8/2022Q2 2022($0.25)($0.21)+$0.04($0.21)$130.06 million$134.56 million 5/4/2022Q1 2022($0.49)($0.70)($0.21)($0.70)$122.22 million$115.47 million 2/28/2022Q4 2021($0.24)($0.27)($0.03)($0.27)$135.44 million$130.80 million 11/8/2021Q3 2021($0.26)($0.09)+$0.17($0.09)$127.77 million$131.61 million 8/3/2021Q2 2021($0.30)($0.27)+$0.03($0.27)$124.94 million$115.22 million 5/4/2021Q1 2021($0.53)($0.42)+$0.11($0.42)$112.91 million$106.55 million ACADIA Pharmaceuticals Earnings - Frequently Asked Questions When is ACADIA Pharmaceuticals's earnings date? ACADIA Pharmaceuticals has confirmed that its next quarterly earnings data will be published on Wednesday, May 8th, 2024. Learn more on ACAD's earnings history. Did ACADIA Pharmaceuticals beat their earnings estimates last quarter? In the previous quarter, ACADIA Pharmaceuticals (NASDAQ:ACAD) missed the analysts' consensus estimate of $0.32 by $0.04 with a reported earnings per share (EPS) of $0.28. Learn more on analysts' earnings estimate vs. ACAD's actual earnings. How can I listen to ACADIA Pharmaceuticals's earnings conference call? The conference call for ACADIA Pharmaceuticals's latest earnings report can be listened to online. Listen to Conference Call How can I read ACADIA Pharmaceuticals's conference call transcript? The conference call transcript for ACADIA Pharmaceuticals's latest earnings report can be read online. Read Transcript How much revenue does ACADIA Pharmaceuticals generate each year? ACADIA Pharmaceuticals (NASDAQ:ACAD) has a recorded annual revenue of $726.44 million. How much profit does ACADIA Pharmaceuticals generate each year? ACADIA Pharmaceuticals (NASDAQ:ACAD) has a recorded net income of -$61.29 million. ACAD has generated -$0.38 earnings per share over the last four quarters. What is ACADIA Pharmaceuticals's EPS forecast for next year? ACADIA Pharmaceuticals's earnings are expected to grow from $0.62 per share to $1.17 per share in the next year, which is a 88.71% increase. More Earnings Resources from MarketBeat Related Companies: MoonLake Immunotherapeutics Earnings Date MorphoSys Earnings Date Arrowhead Pharmaceuticals Earnings Date Indivior Earnings Date Janux Therapeutics Earnings Date IDEAYA Biosciences Earnings Date Amicus Therapeutics Earnings Date Xenon Pharmaceuticals Earnings Date Summit Therapeutics Earnings Date Bausch Health Companies Earnings Date Earnings Tools: Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country: U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Australia Earnings Reports Latest Articles: GE Aerospace is Ready for Liftoff After Strong EarningsTaiwan Semiconductor Earnings: AI Dominance and Future OutlookCSX Co.: The Railroad Powering Ahead with an Earnings Beat What's Driving Tesla Lower Ahead of its Earnings?Blackrock vs. State Street: Earnings in a Volatile MarketWhat to Expect From the Q1 Earnings Reporting SeasonLululemon Stock Implodes Post Earnings, Guidance Muted This page (NASDAQ:ACAD) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarThese AI trades triggered this morning (545% return)Prosper Trading AcademyThe A.I. story nobody is telling you (Read ASAP)TradeSmithRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Priority GoldHe Is Giving Away BitcoinCrypto Swap ProfitsYour Money is Not SafeAmerican Alternative Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ACADIA Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.